title: [Drug patch tests in the investigation of a fixed drug eruption subsequent to 2 courses of cyclophosphamide in combination with mesna].
abstract: BACKGROUND
  When fixed drug eruption occurs following use of cyclophosphamide and mesna, it is difficult to establish which drug is responsible. We report a new case of patch tests that resulted in withdrawal of mesna and enabled continued treatment with cyclophophamide.
  
  
  METHODS
  A 57-year-old female patient with multiple sclerosis presented increasingly severe cutaneous lesions after successive courses of cyclophosphamide. Twenty-four hours after her latest treatment, she presented at the ER with a worse eruption than those to date and including facial lesions. The clinical diagnosis was a fixed drug eruption, and patch tests for mesna one month later were positive.
  
  
  CONCLUSIONS
  Fixed drug eruption always occurs after recurrent treatment and the investigation must be precise. Patch tests may be used to determine which drug could be responsible. The most conclusive test comprises withdrawal of the incriminated drug with no further signs of drug eruption on resumption of the other medication.
authors.affiliation: Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, BP 20545, 83800 Toulon cedex 9, France. Electronic address: delaiguesophie@yahoo.fr.
authors.forename: S
authors.initials: S
authors.lastname: Delaigue
authors.affiliation: Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, BP 20545, 83800 Toulon cedex 9, France.
authors.forename: T
authors.initials: T
authors.lastname: Boye
authors.affiliation: Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, BP 20545, 83800 Toulon cedex 9, France.
authors.forename: C
authors.initials: C
authors.lastname: Pasquine
authors.affiliation: Service d'anatomopathologie, hôpital d'instruction des armées Sainte-Anne, BP 20545, 83800 Toulon cedex 9, France.
authors.forename: K
authors.initials: K
authors.lastname: Guetta
authors.affiliation: Service de neurologie, hôpital d'instruction des armées Sainte-Anne, BP 20545, 83800 Toulon cedex 9, France.
authors.forename: P
authors.initials: P
authors.lastname: Alla
authors.affiliation: Centre de pharmacovigilance, hôpital Salvator, 270, boulevard Sainte-Marguerite, 13274 Marseille cedex 9, France.
authors.forename: J
authors.initials: J
authors.lastname: Ponte-Astoul
authors.affiliation: Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, BP 20545, 83800 Toulon cedex 9, France.
authors.forename: J-J
authors.initials: JJ
authors.lastname: Morand
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015080:Mesna / Q000009:adverse effects*; D008875:Middle Aged; D010328:Patch Tests; D020011:Protective Agents / Q000009:adverse effects*
chemical_list: D018501:Antirheumatic Agents; D020011:Protective Agents; D003520:Cyclophosphamide; D015080:Mesna
keywords: Cyclophosphamide; Fixed drug eruption; Mesna; Tests épicutanés; Toxidermie; Érythème pigmenté fixe